Yahoo Home 
Anjalee Khemlani is a reporter at Yahoo Finance covering all things business, with a focus on health care. Khemlani has previously worked for a variety of media organizations that include startup digital, legacy daily news, international broadcast and local radio. Her most recent position was as a managing editor of ROI-NJ in New Jersey.
Yahoo FinanceJ&J CFO: We've 'beefed up' cardiovascular medical devices in hopes of reviving our medtech business
J&J is doubling down on medtech, a typically sleepy sector that has been risky, as it looks to grow after spinning of consumer health segment Kenvue.
- Yahoo Finance
Walgreens CEO: 'We are on a mission to achieve provider status for our pharmacists'
Walgreens is in the middle of a turnaround strategy. CEO Tim Wentworth sat down with Yahoo Finance to discuss the company's new focus.
- Yahoo Finance Video
Walgreens aims to deliver value as consumers seek relief: CEO
Despite beating analyst expectations on both revenue and earnings in its latest second quarter results, Walgreens Boots Alliance (WBA) narrowed its Adjusted EPS guidance for fiscal year 2024, citing a challenging retail environment. Walgreens CEO Tim Wentworth joins Yahoo Finance Live to shed light on the factors that prompted the decision. Wentworth emphasizes that the "real dynamic" is the strain faced by consumers under current economic conditions. He highlights that consumers are seeking value, and Walgreens is focused on delivering that with the continued sensitivity around pricing. Reflecting on the company's pharmacy business, Wentworth admits that it experienced "a challenging time." However, he states that they have since been able to secure adequate staffing and forge relationships with pharmacy schools to bolster hiring efforts: "We like where we are now." Wentworth explains that the company's efforts extend beyond hiring, but rather "work redesign," allowing pharmacists to "operate at the very top of their clinical ability." Wentworth attributes the negative outlook surrounding Pharmacy Benefit Managers (PBMs) to "consumer, patient dissatisfaction with the way the system works." However, he views this as "an opportunity" to help reshape this outlook. He emphasizes that by concentrating on areas such as value and transparency for consumers, they can aid in transforming this perception, posing the question, "What's the model for the future that's gonna help a PBM help its consumer?" For more expert insight and the latest market action, click here to watch this full episode of Wealth! Editor's note: This article was written by Angel Smith
- Yahoo Finance
Viking Therapeutics stock rises on positive Phase 1 weight-loss pill data
Viking Therapeutics is gearing up to compete with market GLP-1 leaders Novo Nordisk and Eli Lilly.
- Yahoo Finance
Amid increased federal scrutiny, PBMs pivot strategy to further squeeze independent pharmacies
PBMs have used various strategies over the years to squeeze independent pharmacies, and these tactics are on the rise as the federal government takes aim at reigning in the notorious middlemen.
- Yahoo Finance
Moody's says will be 'many years' before big AI impacts are seen in healthcare, pharma
Moody's says pharma and medical device companies are most likely to see the earliest benefits from adopting AI technology.
- Yahoo Finance
UnitedHealth Group top pick despite cyberattack and DOJ setbacks: BofA
UnitedHealth Group's recent cyberattack and DOJ probe are unlikely to be long-term headwinds, according to a BoA analyst.
- Yahoo Finance
UnitedHealth's cyberattack should be a 'wake-up call' for healthcare
UnitedHealth Group faced a cyberattack that froze an important subsidiary in the healthcare ecosystem.
- Yahoo Finance
Communication is key in managing cyberattack: Optum CEO
UnitedHealth Group's Change Healthcare subsidiary is expected to have a "material update" as early as Tuesday following a major ransomware attack that's now on its fifth straight day and stalling care around the country.
- Yahoo Finance
Moderna CEO: 2024 is year of growth, with 2023 transition in rearview
Moderna posted strong results despite investors assuming a loss for the year.
- Yahoo Finance
Novavax resolves Gavi dispute over COVID-19 vaccines
Novavax has resolved a potentially expensive battle with Gavi, opening up a pathway for the company to get out of the red.
- Yahoo Finance
CVS chief medical officer: 'We are not looking to build the entire healthcare delivery ecosystem'
CVS is bullish on its health services outlook, even as the broader industry faces pressure.
- Yahoo Finance
CEO Bertolini: 2024 is the year Oscar will be profitable
Health insurer Oscar Health says it's going to be profitable in 2024.
- Yahoo Finance
GLP-1s: 'We're investing behind this in a big way,' says Amgen CFO
Amgen is focused on price declines while it looks to fill out its portfolio and chase the new obesity market.
- Yahoo Finance
Eli Lilly CFO: Weight-loss drug demand will outstrip GLP-1 supply through 2024
Eli Lilly blew past Wall Street estimates for its latest earnings but faces pressure ahead to deliver strong results for the year.
- Yahoo Finance
The US government has backed 'food as medicine' movement, but does it have staying power?
The US Health Department held a conference to discuss the federal government's efforts to help address food insecurity.
- Yahoo Finance
Seagen acquisition will give Pfizer 'anchor asset' Wall Street desires: Pfizer CEO Bourla
Pfizer beat earnings expectations, but Wall Street is still waiting to see how it pulls out of waning COVID demand and boosts its pipeline with stronger assets to plug a patent cliff at the end of the decade.
- Yahoo Finance
Novo Nordisk earnings: 'I could smile a long time over results like this,' says CFO Knudsen
Novo Nordisk beat Wall Street estimates for 2023, but its 2024 outlook is what investors are keen on watching.
- Yahoo Finance
How a 'complex' Medicare Advantage market left Humana scrambling to start 2024
Humana signaling rough waters ahead after pent-up demand caused the company to realize losses in its Medicare Advantage business in late 2023.
- Yahoo Finance
Why Wall Street no longer fears sprawling impact from the weight loss drug craze
Obesity drugs, known as GLP-1s, continue to be all the rage in 2024. But doomsday predictions of long-term impact to other industries may be cooling.